The scientific community’s fascination with macrocycl by L Liu·2024·Cited by 26—It is worth noting that the 85cyclic peptidestargeting surface glycoproteinsallexhibit antiviral properties [11, 35].Cyclic peptidedetails Read more ic structures has evolved significantly over the last several decades. When we talk about all cyclic peptides ever identified, we are looking at a vast, structural frontier defined by polypeptide chains which contain a circular sequence of bonds. These molecules, ranging from small natural isolates to complex synthetic constructs, represent a dynamic and promising class of bioactive compounds that continue to intrigue researchers worldwide.
Understanding the Structural Architecture
At t C ·Cagrilintide· Cereulide · Chrysosporide · Ciclosporin · Cilengitide · Cinnamycin · Cliotide · Clovibactin · Coibamide A · Colistin · Crustacean Read more heir core, cyclic peptides are defined by their unique topolo How Cyclic Peptides Are Shaping The Future Of Drug gy. Unlike linear counterparts, these are polypeptide chains that are formed by a cyclic sequence of 5 to 14 amino acids, typically exhibiting a molecular weight between 500 and 2000 Da. This "closed-loop" architecture provides immense structural rigidity, which is a primary reason why cyclic peptides are among the most diverse architectures for current drug discovery efforts.
From a historical perspective, the discovery of cyclolinopeptide A (from fla With advanced biotechnology and chemistry, we successfully established a proprietary library of orally available and cell-permeablecyclic peptidesand Read more x) marked a significant milestone in recognizing these structures in nature. Today, we know that they are widely found in nature, isolated from microorganisms, plants, and animals. Early pioneers in this field include the study of oxytocin and vasopressin, which were among the first hormones to highlight the efficacy of cyclic scaffolds.
The Evolution of Clinical Utility
The progression of these molecules from the lab to application is well-documented. Currently, there are over 40 cyclic peptides in clinical use, demonstrating their stability and biological relevance. A notable body of research highlights 18 cyclic peptides approved for clinical use in the past two decades, underscoring a steady rise in their adoption.
Among the notable examples are:
* Cagrilintide: A modern example of an engineered peptide sequence.
* Calcitonin, oxytocin, somatostatin, and vasopressin: The classic hormones that paved the way for the field.
* FDA-approved cyclic peptide drugs: These include specialized agents for various conditions, frequently utilized as molecules that are already used as CycPeptMPDB drugs in therapies.
Data-Driven Insights and Databases
For those tracking the sheer volume of these compounds, the CycPeptMPDB provides a comprehensive look at the field. This database catalogs 7,991 structurally diverse cyclic peptides, offering researchers a centralized knowledge base to study their stability, permeability, and potential for interaction with biological targets. Whether it is custom synthesis of cyclic peptides—involving lactam, disulfide-bridged, or stapled scaffolds—or the exploration of novel "one-pot" synthesis methods, the ability to manipulate these structures has never been greater.
Personal Perspectives on Peptide Research
In my experience exploring the biochemical tools available today, the shift toward these macrocycles is clear. The rigidity of the cyclic bond prevents the rapid degradation often seen in linear peptides, making them highly attractive for those studying protein-protein interactions. While the list of all cyclic peptides continues to grow through high-throughput screening and de novo design, the core appeal remains the same: the perfect balance of size, stability, and specific binding affinity.
As we look toward the future, the integration of computational design and synthetic biol Cyclic Peptides as Therapeutic Agents and Biochemical Tools ogy will likely expand the catalog of these molecules even further. Whether you are reviewing the history of 18 cyclic peptides approved for clinical use in the past two decades or analyzing the latest entries in a specialized database, it is evident that these structures are here to stay, continuing to redefine the by X Ji·2024·Cited by 416—The first cyclic peptide hormones exploited as drugs wereoxytocin and vasopressin, introduced to the clinic in 1960s. Initially identified and Read more boundaries of what is possible in molecular science.